| PUBLICATION DETAILS |
Publication Date
May 1998
|
|
|
|
| DEVELOPED BY |
National Health Committee (NHC)
PO Box 5013
133 Molesworth Street
WELLINGTON
Telephone 64 4 496 2071
Facsimile 64 4 496 2210
Hard copies are not available for all publications. To check, email pubs@moh.govt.nz
or send mail to:
Ministry of Health
C/-Wickliffe Limited
P O Box 932
Dunedin
|
|
|
|
| ENDORSED BY |
|
| REQUIRED TOOLS |
Documents are in PDF format. You'll need the FREE Adobe Acrobat Reader to browse and print them.
|
|
|
| Guidelines for the Management of Heavy Menstrual Bleeding |
| On September 30, 2004, Vioxx (rofecoxib) was withdrawn from the U.S. and worldwide market due to safety concerns of an increased risk of cardiovascular events. See the U.S. Food and Drug Administration (FDA) Web site for more information. Subsequently, on December 23, 2004, the FDA issued a public health advisory concerning the use of non-steroidal anti-inflammatory drug products (NSAIDs) including the COX-2 selective agents Celebrex (celecoxib), Bextra (valdecoxib) and a non-selective NSAID, naproxen (sold as Aleve, Naprosyn and other trade name and generic products). See the FDA web site for more information . |
|
